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We are pleased to announce the launch of Orphanet Jour-
nal of Rare Diseases, an open access, peer-reviewed journal
that will encompass all aspects of rare diseases and
orphan drugs. The focus will be on review articles, but the
journal will consider all contributions that are scientifi-
cally sound and within its scope.
We wish to express our gratitude to the many colleagues
who have agreed to serve as section editors for their spe-
cialties. To a considerable extent, the quality of the journal
will depend on their commitment. The journal's editorial
office is established at the Orphanet headquarters in Paris
and supported by several major institutions including
INSERM, the French Ministry of Health and the European
Commission (DG Public Health and Consumer Protec-
tion).
Traditionally, readers pay to access articles, either through
subscriptions or by paying a fee each time they download
an article. Escalating costs of journal subscriptions have
resulted in libraries subscribing to fewer journals and the
range of articles available to readers is therefore increas-
ingly limited. Although traditional journals publish
authors' work for free (unless there are page or colour
charges), there are limits on how many people can read,
use and cite these articles given the requirement to pay for
access.
Orphanet Journal of Rare Diseases' open access policy
changes the way in which articles are published. First, all
articles become freely and universally accessible online,
and so an author's work can be read by anyone at no cost.
Second, the authors hold copyright for their work and
grant anyone the right to reproduce and disseminate the
article, provided that it is correctly cited and no errors are
introduced. Third, the results of publicly funded research
will be accessible to all taxpayers and not just those with
access to a library with a subscription. As such, open
access holds the potential to increase public interest in,
and support of, research. Fourth, a country's economic
strength will not influence its researchers' ability to access
articles because readers in resource-poor countries (and
institutions) will be able to access the same material as
wealthier ones (access to the internet being the only
requirement).
Article-processing charges will enable Orphanet Journal of
Rare Diseases to serve the scientific community with this
open access forum. We hope you will support this major
advance by submitting articles to our journal. Orphanet
Journal of Rare Diseases will usually levy an article-process-
ing charge for manuscripts accepted after peer review
(payable on acceptance), but will cover the cost of publi-
cation for invited review articles. Many institutions [1]
and research funders [2] will cover article-processing
charges for their researchers.
Please submit your work to Orphanet Journal of Rare Dis-
eases [3]. Help us to contribute to increasing knowledge
on rare diseases for the benefit of the patients and their
families and to assist professionals and researchers work-
ing in the field.
Ségolène Aymé, Bruno Dallapiccola and Dian Donnai
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